Inactive Instrument

Tryp Therapeutics Inc. Share Price OTC Markets

Equities

TRYPF

CA89854F1062

Biotechnology & Medical Research

Delayed OTC Markets 20:17:43 01/05/2024 BST 5-day change 1st Jan Change
0.0562 USD +32.24% Intraday chart for Tryp Therapeutics Inc. +14.69% +64.81%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 7.29M 5.35M 423M
Net income 2024 * -5M -3.67M -290M Net income 2025 * -5M -3.67M -290M EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.31%
More Fundamentals * Assessed data
Dynamic Chart
Tryptamine Therapeutics Limited, formerly Exopharm Limited, is an Australia-based company involved in advancing genetic medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug delivery. The Company invests in biopharmaceutical drug development. The Company is engaged in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes. The Company’s exosome technologies solve the needs for the success of exosome medicines, LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. The Company is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome delivery for their own products.
More about the company